PPCB
Income statement / Annual
Last year (2026), Propanc Biopharma Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2026, Propanc Biopharma Inc's net income was -$18.86 M.
See Propanc Biopharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
06/30/2026 |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.47 K
|
$2.31 K
|
$2.23 K
|
$2.17 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.47 K
|
-$2.31 K
|
-$2.23 K
|
-$2.17 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$625.48 K
|
$223.72 K
|
$248.10 K
|
$247.92 K
|
$256.05 K
|
$230.96 K
|
$179.99 K
|
$260.34 K
|
$1.83 M
|
$971.77 K
|
| General & Administrative Expenses |
$17.56 M
|
$57.05 M
|
$1.29 M
|
$1.50 M
|
$1.71 M
|
$1.58 M
|
$3.28 M
|
$2.33 M
|
$2.10 M
|
$4.74 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$31.00 K
|
$26.00 K
|
$28.00 K
|
$27.00 K
|
| Selling, General & Administrative Expenses |
$17.56 M
|
$57.05 M
|
$1.29 M
|
$1.50 M
|
$1.71 M
|
$1.58 M
|
$3.31 M
|
$2.35 M
|
$2.13 M
|
$4.77 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$28.84 K
|
$28.37 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$18.19 M
|
$57.28 M
|
$1.54 M
|
$1.78 M
|
$1.99 M
|
$1.81 M
|
$3.49 M
|
$2.61 M
|
$3.96 M
|
$5.74 M
|
| Cost And Expenses |
$18.19 M
|
$57.28 M
|
$1.54 M
|
$1.78 M
|
$1.99 M
|
$1.81 M
|
$3.49 M
|
$2.62 M
|
$3.96 M
|
$5.74 M
|
| Interest Income |
$161.00
|
$9.00
|
$60.00
|
$36.00
|
$5.61 K
|
$0.00
|
$946.00
|
$0.00
|
$0.00
|
$685.00
|
| Interest Expense |
$430.54 K
|
$563.76 K
|
$665.84 K
|
$532.82 K
|
$568.80 K
|
$449.46 K
|
$1.75 M
|
$1.32 M
|
$2.79 M
|
$3.20 M
|
| Depreciation & Amortization |
$22.70 K
|
$20.19 K
|
$21.66 K
|
$1.67 K
|
$1.99 K
|
$1.99 K
|
$2.47 K
|
$2.31 K
|
$2.23 K
|
$2.17 K
|
| EBITDA |
-$18.41 M |
-$58.34 M |
-$1.26 M |
-$2.26 M |
-$2.14 M |
-$1.69 M |
-$3.12 M |
-$4.56 M |
-$4.43 M |
-$4.97 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$677.14 K
|
-$1.65 M
|
-$413.61 K
|
-$1.01 M
|
-$722.19 K
|
-$327.00 K
|
-$1.38 M
|
-$3.26 M
|
-$3.26 M
|
-$2.43 M
|
| Income Before Tax |
-$18.86 M
|
-$58.92 M
|
-$1.95 M
|
-$2.79 M
|
-$2.71 M
|
-$2.14 M
|
-$4.88 M
|
-$5.87 M
|
-$7.22 M
|
-$8.17 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$129.13 K
|
-$129.84 K
|
-$54.98 K
|
-$113.00 K
|
-$135.00 K
|
-$115.00 K
|
-$179.00 K
|
-$306.00 K
|
| Net Income |
-$18.86 M
|
-$58.92 M
|
-$1.82 M
|
-$2.66 M
|
-$2.66 M
|
-$2.03 M
|
-$4.74 M
|
-$5.76 M
|
-$7.04 M
|
-$7.87 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-17.62 |
-371.25 |
-0.023675 |
-1.8 |
-0.05 |
-20000 |
-4811228.75 |
-274239389.25 |
-4468737303.25 |
-28018162393.25 |
| EPS Diluted |
-17.62 |
-371.25 |
-0.023675 |
-1.8 |
-0.05 |
-20000 |
-4811228.75 |
-274239389.25 |
-4468737303.25 |
-28018162393.25 |
| Weighted Average Shares Out |
$1.12 M
|
$158.73 K
|
$85.05 M
|
$1.74 M
|
$68.22 M
|
$121.00
|
$0.99
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$1.12 M
|
$158.73 K
|
$85.05 M
|
$1.74 M
|
$68.22 M
|
$121.00
|
$0.99
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
